Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients

Abstract

Background

Antibiotic therapy (ABT)-induced dysbiosis may affect the efficacy of immune checkpoint inhibitors (ICI) therapy. We investigated the association between ABT and real-world overall survival (rwOS) and progression-free survival (rwPFS) in patients with metastatic urothelial carcinoma (mUC) receiving ICI or cisplatin-based chemotherapy (CIS).

Methods

Three thousand, one hundred seventy-nine patients were included from a nationwide electronic health record-derived de-identified database. Three-month landmark Kaplan–Meier methods and log-rank tests were used to estimate rwOS/PFS between treatment modalities based on ABT groups (stratified by exposure, timing, excretion mode, and administration route). Cox proportional models with time-varying coefficients were used to investigate the associations between ABT, treatment modality, and rwOS/PFS.

Results

A total of 402 (27.1%) ICI and 655 (38.6%) CIS patients received ABT (p < 0.001). ICI receipt (OR 0.65, p < 0.001) and advanced age (OR 0.98, p < 0.001) were associated with lower ABT use.

ICI exclusive findings included a negative correlation with rwOS in patients who received post-treatment initiated (ICI median: pre—13.2 vs post—7.9 vs none—13.3 months; p = 0.009), oral (median oral—9.6 vs none—13.3 months, p = 0.03), and renally cleared (median renal—9.9 vs none—13.3 months, p = 0.04) ABT.

ABT’s effect was negatively associated with rwOS in ICI patients within first 6 months (HR 1.36, 95% CI 1.107–1.74, p = 0.01) but not thereafter (p = 0.7).

Conclusions

This study identified a potential ICI-specific negative correlation between ABT and rwOS in patients with mUC, specifically those exposed to ABT pills and receipt before treatment initiation. These results emphasize the importance of antibiotic stewardship and continued investigation of the role of gut microbiome in mUC treatment efficacy.